Sign in

    David Stubbs

    Managing Director at Raymond James

    David Stubbs is a Managing Director at Raymond James in London, specializing in healthcare investment banking with deep expertise in advising middle-market companies in healthcare services, pharmaceuticals, medical technology, diagnostics, biotechnology, and healthcare technology. He has played a key role in over 250 M&A transactions and maintains strong relationships with healthcare-focused equity sponsors, contributing to Raymond James’s reputation as one of the most successful healthcare advisory platforms. Stubbs joined Raymond James with extensive prior experience in investment banking, having built a reputation for leading-edge solutions and strategic insight in the healthcare sector. He is recognized for his domain expertise and holds relevant professional credentials in investment banking.

    David Stubbs's questions to SELLAS Life Sciences Group (SLS) leadership

    David Stubbs's questions to SELLAS Life Sciences Group (SLS) leadership • Q3 2016

    Question

    David Stubbs from Raymond James, on behalf of Ren Benjamin, requested details on the potential Phase III trial for GALE-401, including enrollment, timing, and endpoints, and also asked for guidance on the future cash burn rate.

    Answer

    President & CEO Mark Schwartz explained that the GALE-401 trial will likely target essential thrombocythemia patients who have failed first-line therapy, utilizing an accelerated 505(b)(2) regulatory pathway, and he anticipated trial initiation in Q2 2017. VP Finance John Burns addressed the financials, stating that while Q4 2016 cash burn guidance is $7-$9 million, the burn rate is expected to decrease in 2017 as costs from discontinued operations subside, with more specific guidance to come.

    Ask Fintool Equity Research AI